Pulmonx Corporation (LUNG)

NASDAQ: LUNG · Real-Time Price · USD

2.380

-0.040 (-1.65%)

Aug 28, 2026, 4:00 PM EDT - Market closed

-1.65% (1D)

Market Cap	102.22M +34.9%
Revenue (ttm)	87.44M -3.4%
Net Income	-48.12M
EPS	-1.15
Shares Out	42.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	277,208
Open	2.420
Previous Close	2.420
Day's Range	2.380 - 2.512
52-Week Range	1.130 - 2.890
Beta	0.28
Analysts	Buy
Price Target	3.40 (+42.86%)
Earnings Date	Jul 29, 2026

About LUNG

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with mult... [Read more]

Industry Medical Devices

Sector Healthcare

IPO Date Oct 1, 2020

Employees 296

Stock Exchange NASDAQ

Ticker Symbol LUNG

Website https://pulmonx.com

Full Company Profile

Financial Performance

In 2025, Pulmonx's revenue was $90.50 million, an increase of 8.01% compared to the previous year's $83.79 million. Losses were -$54.00 million, -4.24% less than in 2024.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for LUNG stock is "Buy." The 12-month stock price target is $3.4, which is an increase of 42.86% from the latest price.

Price Target

$3.4

(42.86% upside)

Analyst Consensus: Buy

Stock Forecasts

News

Pulmonx to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that ma...

2 days ago - GlobeNewsWire

Pulmonx management to meet virtually with Lake Street

Virtual Meeting to be held on August 27 hosted by Lake Street.

5 days ago - TheFly

Pulmonx Transcript: Canaccord Genuity's 46th Annual Growth Conference

Sales leadership and territory coverage have stabilized, with junior reps supporting growth and training. Financial guidance remains strong, with improved margins and reduced costs. AeriSeal is set to expand the addressable market by 20% next year, while China revenue is expected to resume early next year.

18 days ago - Transcripts

Pulmonx reports Q2 EPS (24c), consensus (28c)

Reports Q2 revenue $22.75M, consensus $22.39M. “We are pleased with the progress we made in the second quarter executing our commercial strategy, advancing our clinical initiatives, and beginning to d...

4 weeks ago - TheFly

Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.77M

The company said, “Pulmonx (LUNG) continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company now expects gross…

4 weeks ago - TheFly

Pulmonx Earnings Call Transcript: Q2 2026

Q2 2026 revenue reached $22.8M, with net loss and adjusted EBITDA loss both significantly reduced year-over-year. Gross margin improved to 78%, and cost alignment initiatives drove a 16% decrease in operating expenses. Full-year guidance is reaffirmed, with China shipments set to resume in early 2027.

4 weeks ago - Transcripts

Pulmonx Earnings release: Q2 2026

Pulmonx released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.

4 weeks ago - Filings

Pulmonx Quarterly report: Q2 2026

Pulmonx has published its Q2 2026 quarterly earnings report on July 29, 2026.

4 weeks ago - Filings

Pulmonx Reports Second Quarter 2026 Financial Results

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today report...

4 weeks ago - GlobeNewsWire

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the com...

4 weeks ago - GlobeNewsWire

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...

6 weeks ago - GlobeNewsWire

Pulmonx Transcript: AGM 2026

The meeting covered board introductions, voting on director elections, auditor ratification, and executive compensation, with all proposals approved. No shareholder questions were raised, and voting results will be filed with the SEC.

3 months ago - Transcripts

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announ...

3 months ago - GlobeNewsWire

Pulmonx Transcript: Bank of America Global Healthcare Conference 2026

A minimally invasive valve system for severe emphysema has shown strong clinical results and high reimbursement rates, with global reach and a $12 billion addressable market. Recent pipeline expansion and financial restructuring aim to drive renewed growth.

3 months ago - Transcripts

Pulmonx reports Q1 EPS (33c), consensus (33c)

Reports Q1 revenue $20.59M, consensus $20.43M. “During the first quarter we initiated our refreshed U.S. commercial strategies and continued to execute in our direct international markets. We are enco...

4 months ago - TheFly

Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.87M

The company said, “Pulmonx (LUNG) continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company continues to expect…